immunovant inc glp-1 receptor agonist products Schematic illustration of monoagonists, dual agonists and triple Bariatric Fusion GLP Repurposing glucagon-like peptide-1 receptor agonists

Autoimmune diabetes suspected (type 1 diabetes or latent autoimmune diabetes of adults)

Incorporating information about the newer GLP-1 RAs, additional head-to-head studies suggest similar A1C reductions between lixisenatide and exenatide twice daily while showing more weight loss with exenatide twice daily and less GI AEs with lixisenatide [Rosenstock et al

FDA Halts Sale of Off-Brand Ozempic and Other GLP-1 Drugs

The closing of this transaction, subject to regulatory approvals, is expected before the end of 2024

The clear lack of coverage underscores ongoing concerns about the long-term costs and sustainability of using high-priced GLP-1s for weight management without solid evidence of lasting results